Interaction between platelets and endothelium: from pathophysiology to new therapeutic options

Michalis Hamilos, Stylianos Petousis, Fragiskos Parthenakis

Department of Cardiology, University Hospital of Heraklion, Heraklion, Crete, Greece

Abstract: Platelets were traditionally considered to purely have a role in the maintenance of haemostasis. Recently their role in vasomotor function, inflammation and atherosclerosis has been very well-recognized. Endothelium which was originally considered as a simple passive barrier, it is now viewed as an organ whose normal functioning is crucial for maintaining vascular health. When endothelial balance is disturbed, vascular disease initiates. Platelet interactions with endothelium have an important contribution in this process. Low-grade inflammation, endothelial dysfunction, and platelet hyper-reactivity are all independently associated with an increased risk of cardiovascular events. Older antiplatelet agents like aspirin and clopidogrel and newer more potent agents like prasugrel and ticagrelor have been proven effective in all the clinical spectrum of coronary artery disease patients. Current antiplatelet medications and especially newer generation P2Y12 inhibitor ticagrelor, offer clinical benefits not only due to their well-recognized antithrombotic effect, but also via the attenuation of platelet inflammatory action, impediment of P2Y12 activation effects in other cells and through other complex and sometimes undefined pathways. Future research is expected to better define platelet-endothelium interactions and the multiple impact of current antiplatelet therapy on them.

Keywords: Endothelium; platelets; antiplatelet therapy

doi: 10.21037/cdt.2018.07.01
View this article at: http://dx.doi.org/10.21037/cdt.2018.07.01

Introduction

Platelets are the “rulers” of haemostasis and thrombosis, but recently their role in vasomotor function, chemotaxis, inflammation and atherosclerosis has been very well-recognized and extensively studied. The reciprocal and often complex interactions with the endothelium and leucocytes are object of continuous studies and future targeted drug therapies. Low-grade inflammation, endothelial dysfunction, and platelet hyper-reactivity are all independently associated with an increased risk of cardiovascular events. In this context, antiplatelet treatment for patients with coronary artery disease (CAD), beyond its major treatment impact on the reduction of thrombotic events through platelet inhibition, seems to have an important role on platelet and endothelium interplay, by decreasing inflammation, improving endothelial function and decelerating atherosclerosis progression.

This review article describes the cross talk between platelets and endothelial cells (ECs), in particular those who promote atherosclerosis. Moreover, we summarize the current knowledge about the influence of contemporary antiplatelet regimens with their individual characteristics on those complex processes.

Platelets

Platelets are anucleated cells, as they derive from megakaryocytes’ cytoplasmic fragmentation in the bone marrow. Morphologically they have a discoid form and
a diameter of 2–3 μm. Their normal count in humans is 150,000–400,000/μL, with a lifespan of 9–10 days (1).

Platelet’s membrane includes a large number of invaginations that communicate to the outer part through numerous pores resulting in a particularly large surface area called open canalicular system (OCS) (2). Three types of granules can be found in platelet’s cytoplasm. Largest ones are alpha granules whom number is 50–60 per platelet (3). They contain coagulation factors like von Willebrand factor (vWF), fibrinogen, V, XI, XIII factors and growth factors like vascular endothelial growth factor (VEGF), tissue growth factor β (TGF-β), platelet factor 4 (PF-4), P-selectin, thrombospondin, as well as a variety of chemokines. Platelet lysosomes, contain mainly acid hydrolases, cathepsin D and E which are able to degrade glycoproteins, glycolipids and glycosaminoglycans (4). They are implicated in the remodeling of the extracellular matrix and to thrombus regulation.

Dense granules count 4–8 per platelet, containing high concentrations of calcium and phosphates, serotonin and adenosine nucleotides, substances that promote vasoconstriction and platelet aggregation (5). They contain also adhesion proteins such as P-selectin, glycoprotein IIb/IIIa and Ib (GPIIb/IIIa and GPIb). P-selectin, a large adhesion molecule of the selectin family, is expressed in elevated concentrations on platelets surface during platelets activation mediating interactions between ECs, leucocytes and other platelets (6,7). Platelets actions are mediated through a variety of receptors and mediator molecules. GPVI and GPa2b1 integrin represent the main collagen receptors that mediate platelet interactions with subendothelial collagen during primary haemostasis (8). The GPIIb/IX/V receptor complex is composed from four parts, GPIiba, GPIibβ, GPIX and GPV. GPIiba receptor is the principal platelet receptor for vWF (9). The GPIIb/IIIa receptor is composed from two subunits, alpha and beta. It is found on platelets surface in an inactive form and changes structure during platelets activation, having a central role in platelets aggregation (10,11). Fibrinogen, fibronectin, vitronectin and vWF constitute the main ligands of this important receptor.

Protease activated receptors (PAR) which are members of G protein receptors, mediate the action of thrombin, one of the most important activators inducing platelet activation and granule release (12).

Thromboxane A2 (TXA2) is an arachidonic acid product that induces potent platelet activation, aggregation and degranulation, in cooperation with other platelet agonists. These actions are mediated via two isoforms of receptors, TPa which represents the prevalent form on human platelets and TPb, members of the G protein-coupled receptor family (13,14).

Adenosine nucleotides ADP and ATP are involved in platelet adhesion and aggregation. Their actions, mainly driven by ADP, derive from the stimulation of two G protein-coupled receptors, the P2Y1 and P2Y12. The stimulation of P2Y1 receptor results in increased intracellular calcium levels and initiation of platelet shape change and aggregation (15). At the same time, the stimulation of the P2Y12 receptor inhibits adenylyl cyclase activity, resulting in reduction of the intracellular levels of CAMP and subsequent amplification and stabilization of platelets aggregation process, enhancing platelet response to other agonists (15,16).

Endothelium

The entire vascular system is covered by a single strut of ECs. Endothelium which was originally considered as a simple passive barrier, is now viewed as an organ whose normal functioning is crucial for maintaining vascular health and whose dysfunction is crucial in the initiation, progression and clinical complications of vascular disease (17). ECs play an important role in vascular tone, regulating thrombosis and thrombolysis, platelets adherence and activation in order to maintain an undisturbed blood flow under physiologic conditions. At the same time endothelium is of paramount importance in body homeostasis as it regulates the transfer of different molecules through blood vessels (17). The role of the endothelium as a semipermeable barrier is one of its most basic functions. It regulates transport of macromolecules between the vascular lumen and vascular smooth muscle.

Under physiologic conditions platelets circulate without adhering to intact and inactive endothelium. A layer of proteoglycans and glycoproteins is present between ECs and blood, known as glycocalyx (18). This structure regulates endothelium permeability and endothelium interactions with other cells such as platelets and leucocytes, mainly repelling them through its negative charge and limiting the endothelial exposure to adhesion molecules. In addition, prostacyclin, a product of arachidonic acid metabolism in endothelial cells with vasodilating properties, inhibits platelets aggregation by elevating intracellular levels of CAMP (19,20). This substance has a synergistic action with nitric oxide (NO). NO is the most important endothelial derived relaxing factor.
factor and inhibits platelets activation by enhancing the production of guanosine monophosphate (GMP). As a result, intracellular Ca\(^{2+}\) decreases and transformation of GPIIb/IIIa platelet receptor together with the binding of the integrin to fibrinogen is suppressed (19,20) The ecto-ADPase (CD-39), placed on the surface of endothelial cells hydrolyzes both ATP and ADP in order to generate AMP, attenuating platelets reactivity (Figure 1) (19,21). The endothelium is also producing substances with vasoconstrictive and prothrombotic behavior, like TXA2 (22) which promotes platelet aggregation, expresses adhesive co-factors for platelets such as vWF, fibronectin and thrombospondin, and procoagulant factors such as factor V. Endothelial-derived vasoconstrictors are opposing the action of the endothelial-derived vasodilators (23). Most important among them are endothelin-1 (ET-1), angiotensin-II (ANG-II) and vasoconstrictor prostaglandins (24-26). Endothelial dysfunction is a disturbance in normal endothelial function as a consequence of different stimuli or clinical conditions. This disturbed balance may lead to platelets aggregation and adhesion to the endothelium thereby activating it and encouraging leukocyte adhesion, as well as releasing platelet-derived growth factors (PDGFs) that stimulate intimal hyperplasia.

**Platelets and endothelium interaction**

Atherosclerosis is characterized by two parallel operations: infiltration of inflammatory cells and lipid accumulation in the intima of the arterial wall (27). Chronic inflammation defines the evolution of the atherosclerotic plaque, from the earliest stages till its rupture and atherothrombosis. There is growing evidence that platelets, through complex interactions with endothelial and inflammatory cells, play a major role in the initiation and preservation of this process (28-30).

The initiation of atherosclerosis requires the presence of either activated platelets or activated endothelial cells or both (31). A series of pathologic stimuli like hypertension, diabetes mellitus, smoking and dyslipidemia can lead to endothelial dysfunction and triggering of the atherosclerotic process. Oxidant stress and in particular low-density lipoprotein (LDL) accumulation, results in reduced NO levels and triggering of inflammatory pathways (32,33). At the same time oxidized LDL enhances ET-1 expression in ECs, inducing vasoconstriction and proliferation of fibroblasts and vascular smooth muscle cells (VSMCs). In addition, oxidized LDL increases the production and secretion, of fibronectin, thrombospondin and a variety of other glycoproteins, reinforcing leukocytes’ and platelets’ adhesion (Figure 2) (34).

Alternatively circulating activated platelets can secrete inflammatory and mitogenic factors in the local microenvironment, leading to ECs activation and monocytes’ recruitment (35). The initial contact between platelets and endothelial cells is mediated by P-selectin (CD62P),
E-selectin and PSGL-1, which are expressed on the surface of EC during inflammatory processes (36-38). The presence of integrins which are transmembrane receptors mediating cells adhesion on platelets surface, further enhances this binding, leading to a more stable adhesion between platelets and ECs (39,40). Furthermore, ECs express ADAM-15, member of the ADAM (a disintegrin and metalloproteinase) family, a transmembrane cell-surface protein that binds to platelets through the GIIb/IIIa receptor, promoting their activation (41).

Platelets enter in an activation state, releasing a plethora of inflammatory mediators and growth factors such as chemokines, TNF superfamily factors, adhesion proteins and coagulation factors and other mediators further activating the ECs and recruiting monocytes/macrophages (42-45). Chemokines family includes platelet factor 4/CXCL4 that promotes monocyte attraction and differentiation into macrophages (46) as well as inhibition of LDL degradation (47,48), RANTES/CCL5 a major protagonist in leucocyte/monocyte recruitment (49-51), CXCL12/SDF-1, monocyte chemoattractant protein-1 (MCP-1) (52), interleukins (53) and TGF-β1. TNF superfamily factors refers mainly to CD40L/TNFSF5, a monocyte chemoattractant that also enhances the action of metalloproteins and downregulates NO production (54,55) and LIGHT/TNFSF14 (45,56) which is a potent ECs and monocyte/macrophage activator. Adhesion proteins, platelet endothelial cell adhesion molecule (PECAM), P-selectin, fibronectin, vWF, vitronectin and fibrinogen, coagulation factors including plasminogen, protein S, factor V and matrix metalloproteinase are also released. Other mediators participating in this activation state are serotonin, histamine and PDGF. Platelets express also chemokine receptors such as CXCR4, CCR-1, -3, -4 (43) in response to inflammatory signals from ECs and leucocytes that further stimulate them.

The cumulative result of all those substances’ action
is the modulation of biological properties of ECs, leucocytes/monocytes and platelets themselves, in terms of chemotaxis, differentiation, cell adhesion, proliferation and aggregation. In this way platelets promote inflammation in a self-sustaining way preparing the next step which is the formation of atherosclerotic plaque (Figure 3).

**Platelet-leucocyte aggregates (PLAs)**

Activated platelets form aggregates with circulating leucocytes (PLAs) (57-59). The initial binding of platelets to leucocytes is mediated by platelet P-selectin binding to leucocyte PSGL-1. This is followed by further platelets activation by leucocytes, while platelets promote leucocytes transformation in more adhesive and migratory forms, in a continuous interaction. PLAs are circulating in a “sticky” form, roll on endothelium, a process largely mediated by endothelial selectins, activating ECs, promoting monocytes transmigration and formation of atherosclerotic lesions in the vessel wall.

**Platelets and endothelial progenitor cells (EPCs)**

EPCs can be found in peripheral blood as mononuclear cells with a myeloid-endothelial intermediate phenotype,
as they express VEGF receptor-2 (VEGFR-2) but also CD34 and CD133. These cells are involved in vascular repair processes after vascular injury or ischemia. They sustain reendothelialization and neovascularization, via their potential to proliferate and differentiate into endothelial-phenotype cells. The number of those cells in peripheral blood of patients with cardiovascular disease has been shown to predict cardiovascular outcomes. In patients with CAD, EPCs have attenuated migration, proliferation and differentiation. Platelets not only mediate EPCs recruitment at the site of vascular injury, but they also strongly support their proliferation, maturation, differentiation to endothelial-phenotype cells and the acquisition of functional properties such as NO production in vitro (60). Those platelet actions are independent from direct contact between the two cell populations and seem to be mediated through PDGF and basic fibroblast growth factor (BFGF).

**Antiplatelet agents and endothelium**

The last two decades became more evident that complex interactions between platelets, ECs and monocytes/macrophages, determine the evolution of the atherosclerotic lesions, from the early stages to the plaque rupture and atherothrombosis. Antiplatelet therapy is a cornerstone therapy for CAD patients as it prevents thrombotic events. Older antiplatelet agents like aspirin and clopidogrel and newer more potent agents like prasugrel and ticagrelor have been proven effective in all the clinical spectrum of CAD patients, especially those undergoing percutaneous coronary intervention (PCI) or suffering from acute coronary syndromes (ACS). Current antiplatelet medications offer clinical benefits not only due to their well-recognized antithrombotic effect, but also via the attenuation of platelet inflammatory action, impediment of P2Y12 activation effects in other cells and through other pathways. Aspirin remains the basis of antiplatelet therapy for thrombotic events prevention. Aspirin is considered to prevent platelet aggregation by inhibition of platelet cyclooxygenase-1 (COX-1). Since platelet-derived TXA2 synthesis due to irreversible inactivation of platelet cyclooxygenase-1 (COX-1). Since platelet-derived TXA2 increases vessel wall constriction and enhances proliferation of vascular cells (61), inhibition of its synthesis by aspirin may have indirect effects on the interaction between platelets and vascular wall. Hypercholesterolemic mice lacking the TXA2 receptor (TP) develop less atherosclerosis (62), suggesting an anti-atherosclerotic activity of aspirin. Lots of studies have also shown inhibition of experimental vascular inflammation by aspirin, some even at low antiplatelet doses, including the reduction of inflammatory markers (CRP, M-CSF, MCP-1) and pro-inflammatory factors (TXA2, S1P, sICAM-1, IL-6) (63). Aspirin inhibits NO consumption by platelets from healthy subjects, but its beneficial effects on NO bioactivity may be compromised in some hypercholesterolemic patients (64). In the clinical level, platelet inhibition with aspirin has been shown to modulate acetylcholine-induced peripheral vasodilation in patients with atherosclerosis, via inhibition of COX-dependent vasoconstrictors (65). In addition, administration of low dose aspirin seems to improve the endothelium dependent vasodilatation in patients with arterial hypertension (66).

Platelet inhibition by specific GPIIb/IIIa receptor blockade has provided clear evidence of an unequivocal benefit in reducing ischemic events, especially in the setting of ACS patients undergoing PCI. Tirofiban, a selective IIb/IIIa receptor inhibitor, relaxes the coronary artery via an endothelium-dependent NO-cGMP signaling as confirmed by the activation of P3K/Akt/eNOS. Heitzer et al. demonstrated that platelet GPIIIa/IIa receptor blockade with tirofiban and epifibatide improved endothelium-dependent vasodilation in patients with symptomatic CAD (67). The inhibitory effect of the NO synthase inhibitor L-NMMA was significantly increased during platelet GPIIb/IIIa blockade, indicating that the beneficial effect of GPIIb/IIa blockade is mainly owing to enhanced NO bioactivity. Finally, Warnholtz et al. showed that tirofiban can reverse PCI induced endothelial dysfunction in forearm vessels of patients with stable CAD (68).

Platelet P2Y12 inhibitors form a major part of the treatment strategy for patients with CAD due to the importance of the platelet P2Y12 receptor in mediating arterial thrombosis. The most commonly used agents are clopidogrel and the newer and more potent prasugrel and ticagrelor. These agents are selective P2Y12 inhibitors, with different pharmacodynamic and pharmacokinetic properties. Prasugrel and ticagrelor with in vitro and in vivo stronger antiplatelet action than clopidogrel, have proven better clinical efficacy than clopidogrel, showing less thrombotic events in large ACS populations, with the cost of increased bleeding events. Besides platelet’s activation and thrombus formation, P2Y12 receptor activation leads also to reduce platelets NO responsiveness and reinforces the production of reactive oxygen species (ROS). ROS can further activate platelets, enhance platelets-leukocytes interactions and...
accelerate lipids oxidation and inflammation processes. P2Y12 receptors expression can be also found in other cells, such as leukocytes, dendritic cells, VSMC, endothelial cells and neurons (69). In ECs the activation of P2Y12 receptor decreases the intracellular CAMP concentration, with negative effects on endothelial barrier functions promoting VSMC contraction and vasoconstriction.

In patients with stable CAD, clopidogrel treatment is associated with improvement of forearm blood flow and reduction in values of inflammation and oxidative stress biomarkers (70). Warnholtz et al. showed that clopidogrel administration in patients with CAD, improved endothelial function assessed by measurement of flow mediated dilation of the brachial artery, in a dose dependent relationship (71). Consistently, Patti et al. in ARMYDA-150mg study revealed that in patients undergoing PCI, administration of 150 mg clopidogrel instead of 75 mg as a maintenance dose in addition to aspirin, resulted in higher platelet inhibition, amelioration of endothelial function and reduction of inflammatory indices (72). Bonello et al. [2010] showed that adequate platelet inhibition in response to clopidogrel treatment attenuates endothelial injury estimated with the number of circulating endothelial cells (73). Muller et al. demonstrated that endothelial dysfunction, (evaluated with endothelial peripheral arterial tonometry, vWF antigen level and ristocetin co-factor activity) is associated with a greater residual platelet reactivity after 600 mg clopidogrel administration before scheduled PCI (74). In another study from the same group, a significant proportionate improvement of endothelial function was achieved after 600 mg clopidogrel loading dose in patients with low residual platelet reactivity after 600 mg clopidogrel administration before scheduled PCI (75). In another study from the same group, a significant proportionate improvement of endothelial function was achieved after 600 mg clopidogrel loading dose in patients with low residual platelet reactivity after 600 mg clopidogrel administration before scheduled PCI (76). Fujisue et al. showed that endothelial function evaluated with peripheral arterial tonometry was impaired in patients with residual platelet reactivity ≥230 PRU after administration of aspirin and clopidogrel, in a group that lacked CYP2C19*2 or *3 loss of function allele (77). However, in another study Haynes et al. did not find any significant relationship between endothelial function evaluated with flow mediated dilation and platelets activation evaluated with flow cytometric determination of GPIIb/IIIa activation, surface P-selectin expression and presence of monocyte-platelet aggregates (78). Those controversies might be explained due to the different methods used for endothelial function and platelet activation evaluation and the different study populations.

Prasugrel, similar to clopidogrel, is a prodrug requiring hepatic metabolism to generate an active metabolite that acts as an irreversibly binding P2Y12 antagonist. Prasugrel improves mid-term vascular dysfunction and inflammation in patients with unstable angina. It is also associated with a reduction of platelet-derived inflammatory markers and platelet-leukocyte interaction (79).

Ticagrelor seems to offer additional benefits than clopidogrel and prasugrel on endothelial function (80). Ticagrelor beyond its profound platelet inhibition seems to enhance adenosine levels by blocking adenosine reuptake in blood cells (81), resulting in vessels dilatation. In addition, it causes ATP release from red blood cells (82), enhancing the endothelium release of vasodilatory mediators such as prostacyclin, NO and endothelial hyperpolarizing factor. In CLOTILDA STUDY 42 patients with diabetes mellitus and stable coronary disease were randomly assigned to receive either ticagrelor or clopidogrel (83). Brachial artery reactivity, as well as post treatment platelet inhibition with VerifyNow assay was evaluated in all patients. The results of this study suggested that ticagrelor, besides a more potent platelet inhibition, caused a significant improvement of brachial artery vascular tone, both by endothelial function amelioration and with enhancement of nitroglycerin-mediated dilation, an endothelium independent mechanism. Furthermore, Tornigren et al. found that in ACS patients, ticagrelor administration was associated with improvement of endothelial function, a benefit that was not observed in patients receiving clopidogrel or prasugrel (84). Similar encouraging results were observed in animal models, concerning ticagrelor’s impact on atherosclerosis initiation and progression. Rusnak et al. showed stabilization of fibrous cap size and necrotic core extension of an already established atherosclerotic plaque in mice after 25 weeks of ticagrelor treatment (85). In other animal models ticagrelor seems to attenuate neointimal formation or hyperplasia (86,87). Interestingly ticagrelor exerts beneficial effects on endothelium also through other pathways. Bonello et al. found that patients treated with ticagrelor had an important increase in numbers of circulating EPCs of CD34+133PC and CD34+KDR+EPC types, compared to clopidogrel treated patients (88). This effect of ticagrelor was independent of platelet activity and may contribute to endothelial repair-regeneration processes. Ticagrelor beyond P2Y12 reversible inhibition appears to have additional antithrombotic properties. Tissue factor (TF)
is the molecule that promotes the extrinsic coagulation cascade and it is expressed in different cells, including endothelial cells. Patients with cardiovascular risk factors or ACS seem to have elevated levels of TF. Reiner et al. studied TF expression and activity in human aortic endothelial cells, treated with ticagrelor or clopidogrel active metabolite (CAM), after stimulation with TNF-α, a molecule that promotes TF expression and activity. They found that ticagrelor unlike CAM, attenuated both TNF-α induced endothelial expression through proteasomal degradation, as well as TF activity itself (89). These results showed that ticagrelor exhibits endothelial-specific antithrombotic properties independent from P2Y12 receptor inhibition. Those findings were confirmed in ticagrelor-treated mice where attenuated endothelial TF expression levels were observed. A summary of all the clinical studies showing the impact of antiplatelet treatment on endothelial function is shown in the Table 1.

**Future perspectives**

Platelet interactions with endothelium have a well-recognized, important contribution to atherosclerosis progression and to atherothrombosis related clinical events. Antiplatelet agents seem in general to interfere to this process beyond their pure antiplatelet action by improving...
endothelial function. This might be a direct effect but there are indications that the more potent the antiplatelet action is the more improvement in endothelial function is observed. Moreover, there are pleiotropic actions of some newer antiplatelet agents like ticagrelor, that may further help to reduce vascular inflammation, endothelial dysfunction and atherogenesis beyond its class effect. Whether those observations can be translated in clinically significant reduction of atherosclerotic plaque progression is a first important question. A second question is whether new agents can target platelet endothelium interactions in a more specific way, “blocking” some part of atherosclerosis progression. There are some preliminary data in a porcine model, showing that ticagrelor improves endothelial function and reduces neointimal formation and peri-strut inflammation after drug-eluting stent (DES) implantation while potent platelet inhibition by prasugrel did not result in any such effects (90). Those findings are promising in the clinical level as ticagrelor therapy might reduce in stent restenosis after PCI due to reduced inflammation and improved macro and micro vascular endothelial function. In addition, the armamentarium against atherosclerosis has been significantly enriched recently. Beyond the newer potent antiplatelet agents and their potential to act against plaque progression, newer agents targeting to cholesterol lowering have been added to everyday clinical practice. Monoclonal antibodies acting as PCSK-9 inhibitors reduce impressively LDL-C when added to maximally tolerated statin therapy, improving patient's clinical outcome (91,92). Moreover, they have shown significant coronary plaque regression and could provide additional gain in ACS patients through plaque stabilization, anti-inflammatory or antiplatelet effects (93). Possible synergistic effects of those agents with intensive platelet inhibition could provide further clinical benefit in patients with CAD. Answers to those and other similar questions are expected from future bench and clinical studies.

Conclusions

Platelets together with endothelium have a major role in inflammation and atherosclerosis progression. Today it is a common knowledge that platelet's inhibition can reduce endothelial dysfunction, vessel wall inflammation and attenuate atherosclerosis progression and atherothrombotic events. Concerning that antiplatelet agents beyond platelet inhibition have differential interactions with endothelium and vessel wall, tailored antiplatelet regimens, depending on atherosclerosis extent, type of interventions and possible modification of vessel wall inflammation might help improving outcomes in the clinical level. Most of the present data although experimental or coming from small clinical series, hold promise for further development of the antiplatelet armamentarium and give motivation for larger clinical studies.

Acknowledgements

None.

Footnote

Conflicts of Interest: M Hamilos has received speaker fees and participated in advisory boards for Astra-Zeneca. The other authors have no conflicts of interest to declare.

References

the binding of fibrinogen and platelet aggregation. Blood 1987;70:475-83.
40. Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-


